1887

Chapter 7 : Mycotic Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Mycotic Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch7-1.gif /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch7-2.gif

Abstract:

The number of fungal species is conservatively estimated to be 1.5 million, and at least 98,000 have been described formally (1). Although more than 300 of these are documented as causing disease in humans, only about 100 are encountered regularly as pathogens of humans. Virulence among these fungi varies, as do the entry portals through which they cause disease in the host and the manner in which they subsequently could spread. These various differences provide a convenient basis for broadly categorizing the mycoses, and they also help in delineating biosafety measures needed for the safe handling and storage of the fungi involved.

Citation: Schell W. 2017. Mycotic Agents, p 147-162. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch7
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Spore formation provides an efficient mechanism for dispersal of molds. Spores from some species pose a risk of infection to laboratory personnel. In this image of cells of a vegetative hypha have transformed into spores (arrows) that will be liberated when walls of the adjacent cells, now dead and withered, become fractured (arrowheads).

Citation: Schell W. 2017. Mycotic Agents, p 147-162. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819637.ch7
1. Kirk PM, Canon PF, Minter DW, Stalpers JM (ed). 2008. Dictionary of the Fungi, 10th ed. CAB International, Wallingford, U.K.
2. de Hoog GS, Guarro J, Gené J, Figueras MJ (ed). 2009. Atlas of Clinical Fungi, 3rd ed. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
3. de Hoog GS, Guarro J, Gené J, Figueras MJ (ed). 2000. Atlas of Clinical Fungi, 2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
4. Merz WG, Hay RJ (ed). 2005. Medical Mycology, 10th ed. Hodder Arnold, London.
5. Anaissie EJ, McGinnis MR (ed). 2009. Clinical Mycology, 2nd ed. Churchill Livingstone, London.
6. Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (ed). 2010. Essentials of Clinical Mycology, 2nd ed. Springer, New York.
7. Howard DH (ed). 2003. Pathogenic Fungi in Humans and Animals, 2nd ed. Marcel Dekker, Inc., New York.
8. Gilgado F, Cano J, Gené J, Sutton DA, Guarro J. 2008. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. J Clin Microbiol 46:766771.[CrossRef][PubMed]
9. Park B, Park J, Cheong KC, Choi J, Jung K, Kim D, Lee YH, Ward TJ, O'Donnell K, Geiser DM, Kang S. 2011. Cyber infrastructure for Fusarium: three integrated platforms supporting strain identification, phylogenetics, comparative genomics and knowledge sharing. Nucleic Acids Res 39(Database):D640D646.[CrossRef][PubMed]
10. Morris SK, Nguyen CK. 2004. Blastomycosis. Univ Toronto Med J 81:172175.
11. Department of Health and Human Services, National Institutes of Health. 2009. NIH Guidelines for Research Involving Recombinant DNA Molecules. 2016 Guidelines http://osp.od.nih.gov/sites/default/files/NIH_Guidelines.html.
12. Halde C, Valesco M, Flores M. 1992. The need for a mycoses reporting system. Curr Top Med Mycol 4:259265.[CrossRef][PubMed]
13. Department of Agriculture. 2005. Part II. Agricultural Bioterrorism Protection Act of 2002; Possession, Use, and Transfer of Biological Agents and Toxins; Final Rule. 70. Title 7 CFR Part 331 and Title 9 CFR Part 121.
14. Department of Health and Human Services. 2005. Part III. Possession, use, and transfer of Select Agents and Toxins; Final Rule, 70. Title 42 CFR 72 and 73, Office of the Inspector General 42 CFR Part 1003.
15. Chamberlain AT, Burnett LC, King JP, Whitney ES, Kaufman SG, Berkelman RL. 2009. Biosafety training and incident-reporting practices in the united States: A 2008 Survey of biosafety professionals. Appl Biosaf 14:135143.[CrossRef][PubMed]
16. Kimman TG, Smit E, Klein MR. 2008. Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures. Clin Microbiol Rev 21:403425.[CrossRef][PubMed]
17. Schwarz J,. 1983. Laboratory infections with fungi, p 215227. In Di Salvo AF (ed), Occupational Mycoses. Lea & Febiger, Philadelphia.
18. Centers for Disease Control and Prevention and National Institutes of Health. 2009. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. U.S. Department of Health and Humans Services, Washington, DC.
19. Zerwekh JT, Emery RJ, Waring SC, Lillibridge S. 2004. Using the results of routine laboratory workplace surveillance activities to assess compliance with recommended biosafety guidelines. Appl Biosaf 9:7683.[CrossRef]
20. Fisher MC, Koenig GL, White TJ, Taylor JW. 2002. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 94:7384.[CrossRef][PubMed]
21. Department of Health and Human Services. 2002. Part IV. Possession, use and transfer of select agents and toxins; Interim Final Rule, 67. Title 42 CFR Part 73 Title 42 CFR Part 1003.
22. Department of Agriculture. 2002. Agricultural Bioterrorism Protection Act of 2002. Possession, Use, and Transfer of Biological Agents and Toxins; Interim Final Rule, 67. 7 CFR Part 331 and 9 CFR Part 121.
23. Odds FC. 1988. Candida and Candidosis, 2nd ed. Baillière Tindall, London, United Kingdom.
24. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. 2007. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271276.[CrossRef][PubMed]
25. Schell WA. 2000. Histopathology of fungal rhinosinusitis. Otolaryngol Clin North Am 33:251276.[CrossRef][PubMed]
26. Public Health Agency of Canada. 2016. Candida albicans—pathogen safety data sheet. Public Health Agency of Canada, Ottawa. http://www.phacaspc.gc.ca/labbio/res/psdsftss/msds30eeng.php
27. MacCallum DM, Odds FC. 2004. Safety aspects of working with Candida albicans-infected mice. Med Mycol 42:305309.[CrossRef][PubMed]
28. Perfect JR, Schell WA. 2004. Laboratory-acquired Candida albicans skin infection. Personal Commnication.
29. Litvintseva AP, Kestenbaum L, Vilgalys R, Mitchell TG. 2005. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol 43: 556564.[CrossRef][PubMed]
30. Bartlett K, Byrnes EJIII, Duncan C, Fyfe M, Galanis E, Heitman J, Hoang L, Kidd S, MacDougall L, Mak S, Marr K,. 2011. The Emergence of Cryptococcus gattii infections on Vancouver Island and expansion in the Pacific Northwest, p 313325. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: From Human Pathogen to Model Yeast. ASM Press, Washington, DC.[CrossRef]
31. Harris J, Lockhart S, Chiller T. 2012. Cryptococcus gattii: where do we go from here? Med Mycol 50:113129.[CrossRef][PubMed]
32. Perfect JR, Casadevall A. 2002. Cryptococcosis. Infect Dis Clin North Am 16:837874, v–vi. PubMed PMID: 12512184.
33. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L-a, Niang R, Casadevall A. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:e66.[CrossRef][PubMed]
34. Hsueh Y, Lin X, Kwon-Chung KJ, Heitman J,. 2011. Sexual reproduction of Cryptococcus, p 8196. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: From Human Pathogen to Model Yeast. ASM Press, Washington, DC.[CrossRef]
35. Glaser JB, Garden A. 1985. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med 313:266.[CrossRef][PubMed]
36. Casadevall A, Mukherjee J, Yuan R, Perfect J. 1994. Management of injuries caused by Cryptococcus neoformans–contaminated needles. Clin Infect Dis 19:951953.[CrossRef][PubMed]
37. Beyt BE Jr, Waltman SR. 1978. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 298:825826.[CrossRef][PubMed]
38. Perry HD, Donnenfeld ED. 1990. Cryptococcal keratitis after keratoplasty. Am J Ophthalmol 110:320321.[CrossRef][PubMed]
39. Tragiannidis A, Bisping G, Koehler G, Groll AH. 2010. Minireview: Malassezia infections in immunocompromised patients. Mycoses 53:187195.[CrossRef][PubMed]
40. Martino R, Salavert M, Parody R, Tomás JF, de la Cámara R, Vázquez L, Jarque I, Prieto E, Sastre JL, Gadea I, Pemán J, Sierra J. 2004. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 38: 335341.[CrossRef][PubMed]
41. Pfaller MA, Diekema DJ. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:44194431.[CrossRef][PubMed]
42. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. 2003. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 41:52335235.[CrossRef][PubMed]
43. Miller JD, Rand TG, Jarvis BB. 2003. Stachybotrys chartarum: cause of human disease or media darling? Med Mycol 41: 271291.[CrossRef][PubMed]
44. DeVries JW, Trucksess MW, Jackson LS (ed). 2002. Mycotoxins and Food Safety. Kluwer Academic/Plenum Publishers, New York, N.Y.[CrossRef]
45. Committee on Damp Indoor Spaces and Health, Board on Health Promotion and Disease Prevention. 2004. Damp Indoor Spaces and Health, p. 1213. The National Academies Press, Washington, DC.
46. Sorenson WG,. 2001 Occupational respiratory disease: organic dust toxic syndrome, p 145153. In Flannigan B, Samson RA, Miller JD (ed), Microorganisms in Home and Indoor Work Environments. Taylor & Francis, London, England.
47. Jarvis BB,. 2002; Chemistry and toxicology of moulds isolated from water-damaged buildings, p 4352. In DeVries JW, Trucksess MW, Jackson LS (ed), Mycotoxins and Food Safety. Kluwer Academic/Plenum Publishers, New York, NY.
48. Pestka JJ, Yike I, Dearborn DG, Ward MD, Harkema JR. 2008. Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. Toxicol Sci 104:426.[CrossRef][PubMed]
49. Clancy CJ, Nguyen MH. 1998. Acute community-acquired pneumonia due to Aspergillus in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. Chest 114:629634.[CrossRef][PubMed]
50. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250260.[CrossRef][PubMed]
51. Knutsen AP, Slavin RG. 2011. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol 2011:843763.[CrossRef][PubMed]
52. Anderson LL, Giandoni MB, Keller RA, Grabski WJ. 1995. Surgical wound healing complicated by Aspergillus infection in a nonimmunocompromised host. Dermatol Surg 21:799801.[CrossRef][PubMed]
53. Sawyer RG, Schenk WG III, Adams RB, Pruett TL. 1992. Aspergillus flavus wound infection following repair of a ruptured duodenum in a non-immunocompromised host. Scand J Infect Dis 24:805809.[CrossRef][PubMed]
54. Hope WW, Walsh TJ, Denning DW. 2005. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43(Suppl 1):207238.[CrossRef][PubMed]
55. Ferguson BJ. 2000. Definitions of fungal rhinosinusitis. Otolaryngol Clin North Am 33:227235.[CrossRef][PubMed]
56. Deshazo RD. 2009. Syndromes of invasive fungal sinusitis. Med Mycol 47(Suppl 1):S309S314.[CrossRef][PubMed]
57. Stringer SP, Ryan MW. 2000. Chronic invasive fungal rhinosinusitis. Otolaryngol Clin North Am 33:375387.[CrossRef][PubMed]
58. Burgess JW, Schwan WR, Volk TJ. 2006. PCR-based detection of DNA from the human pathogen Blastomyces dermatitidis from natural soil samples. Med Mycol 44:741748.[CrossRef][PubMed]
59. Lortholary O, Dupont B,. 2010. Fungal Infections Among Patients with AIDS, p 525. In Kauffman CA, Pappas PG, Sobel J, Dismukes WE (ed), Essentials of Clinical Mycology, 2nd ed. Springer, New York.
60. Velázquez R, Muñoz-Hernández B, Arenas R, Taylor ML, Hernández-Hernández F, Manjarrez ME, López-Martínez R. 2003. An imported case of Blastomyces dermatitidis infection in Mexico. Mycopathologia 156:263267.[CrossRef][PubMed]
61. Marty P, Brun S, Gari-Toussaint M. 2000. [Systemic tropical mycoses]. Med Trop (Mars) 60:281290.[PubMed]
62. Denton JF, Di Salvo AF, Hirsch ML. 1967. Laboratory-acquired North American blastomycosis. JAMA 199:935936.[CrossRef][PubMed]
63. Harrell ER, Curtis AC. 1959. North American blastomycosis. Am J Med 27:750766.[CrossRef]
64. Baum GL, Lerner PI. 1970. Primary pulmonary blastomycosis: a laboratory-acquired infection. Ann Intern Med 73:263265[CrossRef].[PubMed]
65. Larsh HW, Schwarz J. 1977. Accidental inoculation blastomycosis. Cutis 19:334335, 337.[PubMed]
66. Barker BM, Jewell KA, Kroken S, Orbach MJ. 2007. The population biology of coccidioides: epidemiologic implications for disease outbreaks. Ann N Y Acad Sci 1111:147163.[CrossRef][PubMed]
67. Verghese S, Arjundas D, Krishnakumar KC, Padmaja P, Elizabeth D, Padhye AA, Warnock DW. 2002. Coccidioidomycosis in India: report of a second imported case. Med Mycol 40:307309.[CrossRef][PubMed]
68. Singh K. 2009. Laboratory-acquired infections. Clin Infect Dis 49:142147.[CrossRef][PubMed]
69. Trimble JR,, Doucette J. 1956. Primary cutaneous coccidioidomycosis; report of a case of a laboratory infection. AMA Arch Derm 74:405410.[CrossRef][PubMed]
70. Pappagianis D,. 2005. Coccidioidomycosis, p 502518. In Merz WG, Hay RJ (ed), Medical Mycology. Hodder Arnold, London, UK.
71. Gaidici A, Saubolle MA. 2009. Transmission of coccidioidomycosis to a human via a cat bite. J Clin Microbiol 47:505506.[CrossRef][PubMed]
72. Schell WA,. 2003. Dematiaceous Hyphomycetes, p 565636. In Howard DH (ed), Pathogenic Fungi in Humans and Animals. Marcel Dekker, New York, N.Y.
73. Mendoza N, Arora A, Arias C, Hernandez C, Madkam V, Tyring S,. 2009. Cutaneous and subcutaneous mycoses, p 509523. In Anaissie EJ, McGinnis MR, Pfaller MA (ed), Clinical Mycology, 2nd ed Elsevier, Inc.
74. Morris A, Schell WA, McDonagh D, Chaffee S, Perfect JR. 1995. Pneumonia due to Fonsecaea pedrosoi and cerebral abscesses due to Emericella nidulans in a bone marrow transplant recipient. Clin Infect Dis 21:13461348.[CrossRef][PubMed]
75. Jabeen K, Farooqi J, Zafar A, Jamil B, Mahmood SF, Ali F, Saeed N, Barakzai A, Ahmed A, Khan E, Brandt ME, Hasan R. 2011. Rhinocladiella mackenziei as an emerging cause of cerebral phaeohyphomycosis in Pakistan: a case series. Clin Infect Dis 52:213217.[CrossRef][PubMed]
76. Horré R, De Hoog GS. 1999. Ecology and evolution of black yeasts and their relatives. Studies Mycol 43:176193.
77. Schell WA, Salkin IF, McGinnis MR,. 2003. Bipolaris, Exophiala, Scedosporium, Sporothrix, and other dematiaceous fungi, p 825846. In Murray P , et al (ed), Manual of Clinical Microbiology. 2, 8th ed. ASM Press, Washington, D.C.
78. Sigler L,. 2003. Miscellaneous opportunistic fungi: Microascaceae and other ascomycetes, hyphomycetes, coelomycetes and basidiomycetes, p 637676. In Howard DH (ed), Pathogenic Fungi in Humans and Animals, 2nd ed. Marcel Dekker, New York.
79. Defontaine A, Zouhair R, Cimon B, Carrère J, Bailly E, Symoens F, Diouri M, Hallet JN, Bouchara JP. 2002. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 40:21082114.[CrossRef][PubMed]
80. Williamson EC, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJ. 2001. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol 39:4750.
81. Kane JR, Summerbell R, Sigler L, Krajden S, Land G. 1997. Laboratory Handbook of Dermatophytes: A Clinical Guide and Laboratory Manual of Dermatophytes and Other Filamentous Fungi from Skin, Hair, and Nails. Star Publishing Co., Belmont, CA.
82. Collins CH, Kennedy DA. 1999. Laboratory-Acquired Infections: History, Incidence, Causes and Prevention, 4th ed. Butterworth Heinemann, Oxford, UK.
83. Sewell DL. 1995. Laboratory-associated infections and biosafety. Clin Microbiol Rev 8:389405.[PubMed]
84. Schell WA. 1995. New aspects of emerging fungal pathogens. A multifaceted challenge. Clin Lab Med 15:365387.[PubMed]
85. Liu K, Howell DN, Perfect JR, Schell WA. 1998. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 109:4554.[CrossRef][PubMed]
86. Dignani MC, Anaissie E. 2004. Human fusariosis. Clin Microbiol Infect 10(Suppl 1):6775.[CrossRef][PubMed]
87. Schell WA. 2000. Unusual fungal pathogens in fungal rhinosinusitis. Otolaryngol Clin North Am 33:367373.[CrossRef][PubMed]
88. Tesh RB, Schneidau JD Jr. 1966. Primary cutaneous histoplasmosis. N Engl J Med 275:597599.[CrossRef][PubMed]
89. Tosh FE, Balhuizen J, Yates JL, Brasher CA. 1964. Primary cutaneous histoplasmosis. Report of a case. Arch Intern Med 114:118119.[CrossRef][PubMed]
90. Buitrago MJ, Gonzalo-Jimenez N, Navarro M, Rodriguez-Tudela JL, Cuenca-Estrella M. 2011. A case of primary cutaneous histoplasmosis acquired in the laboratory. Mycoses 54:e859e861.[CrossRef][PubMed]
91. Spicknall CG, Ryan RW, Cain A. 1956. Laboratory-acquired histoplasmosis. N Engl J Med 254:210214.[CrossRef][PubMed]
92. Sun HY, Singh N. 2011. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 11:301311.[CrossRef][PubMed]
93. Van Damme PA, Bierenbroodspot F, Telgtt DSC, Kwakman JM, De Wilde PCM, Meis JFGM. 2006. A case of imported paracoccidioidomycosis: an awkward infection in The Netherlands. Med Mycol 44:1318.[CrossRef][PubMed]
94. Madsen AM. 2011. Occupational exposure to microorganisms used as biocontrol agents in plant production. Front Biosci (Schol Ed) 3:606620.[CrossRef][PubMed]
95. Orth B, Frei R, Itin PH, Rinaldi MG, Speck B, Gratwohl A, Widmer AF. 1996. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 125:799806.[CrossRef][PubMed]
96. Castro LG, Salebian A, Sotto MN. 1990. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections. J Med Vet Mycol 28:1526.[CrossRef][PubMed]
97. Innocenti P, Pagani E, Vigl D, Höpfl R, Huemer HP, Larcher C. 2011. Persisting Paecilomyces lilacinus nail infection following pregnancy. Mycoses 54:e880e882.[CrossRef][PubMed]
98. Rockhill RC, Klein MD. 1980. Paecilomyces lilacinus as the cause of chronic maxillary sinusitis. J Clin Microbiol 11:737739.[PubMed]
99. Fletcher CL, Hay RJ, Midgley G, Moore M. 1998. Onychomycosis caused by infection with Paecilomyces lilacinus. Br J Dermatol 139:11331135.[CrossRef][PubMed]
100. Segretain G. 1959. Penicillium marneffei n. sp., agent d'une mycose du systeme reticulo-endothelial. Mycopathol Mycol Appl 11:327353[CrossRef].
101. Hilmarsdottir I, Coutellier A, Elbaz J, Klein JM, Datry A, Guého E, Herson S. 1994. A French case of laboratory-acquired disseminated Penicillium marneffei infection in a patient with AIDS. Clin Infect Dis 19:357358.[CrossRef][PubMed]
102. Kauffman CA. 1999. Sporotrichosis. Clin Infect Dis 29:231236, quiz 237.[CrossRef][PubMed]
103. Galhardo MCG, Silva MTT, Lima MA, Nunes EP, Schettini LEC, de Freitas RF, Paes RA, Neves ES, do Valle ACF. 2010. Sporothrix schenckii meningitis in AIDS during immune reconstitution syndrome. J Neurol Neurosurg Psychiatry 81:696699.[CrossRef][PubMed]
104. Harrell ER. 1964. Occupational Diseases Acquired from Animals. The University of Michigan School of Public Health, Ann Arbor, MI.
105. Dunstan RW, Reimann KA, Langham RF. 1986. Feline sporotrichosis. J Am Vet Med Assoc 189:880883.[PubMed]
106. Cooper CR, Dixon DM, Salkin IF. 1992. Laboratory-acquired sporotrichosis. J Med Vet Mycol 30:169171.[CrossRef][PubMed]
107. Cooper CR Jr, Breslin BJ, Dixon DM, Salkin IF. 1992. DNA typing of isolates associated with the 1988 sporotrichosis epidemic. J Clin Microbiol 30:16311635.[PubMed]
108. Forester HR. 1924. Sporotrichosis. Am J Med Sci 167:5576.
109. Jin XZ, Zhang HD, Hiruma M, Yamamoto I. 1990. Mother-and-child cases of sporotrichosis infection. Mycoses 33:3336.[PubMed]
110. Barros MB, Schubach TP, Coll JO, Gremião ID, Wanke B, Schubach A. 2010. [Sporotrichosis: development and challenges of an epidemic]. Rev Panam Salud Publica 27:455460.[PubMed]
111. Barros MB, Schubach AO, do Valle AC, Gutierrez Galhardo MC, Conceição-Silva F, Schubach TM, Reis RS, Wanke B, Marzochi KB, Conceição MJ. 2004. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis 38:529535.[CrossRef][PubMed]
112. Arenas R,. 2005. Sporotrichosis, p 367384. In Merz WG, Hay RJ (ed), Topley & Wilson's Microbiology and Microbial Infecctions. Medical Mycology. Hodder Arnold, London, UK.
113. Frean JA, Isaäcson M, Miller GB, Mistry BD, Heney C. 1991. Sporotrichosis following a rodent bite. A case report. Mycopathologia 116:58.[CrossRef][PubMed]
114. Moore JJ, Davis DJ. 1918. Sporotrichosis following mouse bite with certain immunologic data. J Infect Dis 23:252265.
115. Kwon-Chung KJ, Bennett JE. 1992. Medical Mycology. Lea & Febiger, Philadelphia, PA.
116. Reid JD, Scherer JH, Herbut PA, Irving H. 1942. Systemic histoplasmosis. J Lab Clin Med 27:419434.
117. Daniels LS, Berliner MD, Campbell CC. 1968. Varying virulence in rabbits infected with different filamentous types of Histoplasma capsulatum. J Bacteriol 96:15351539.[PubMed]
118. Nosanchuk JD, Mednick A, Shi L, Casadevall A. 2003. Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci 42:912.[PubMed]
119. Ajello L, Weeks RJ,. 1983. Soil decontamination and other control measures, p 229238. In DiSalvo AF (ed), Occupational Mycoses. Lea & Febiger, Philadelphia, PA.
120. Cole GT, Xue JM, Okeke CN, Tarcha EJ, Basrur V, Schaller RA, Herr RA, Yu JJ, Hung CY. 2004. A vaccine against coccidioidomycosis is justified and attainable. Med Mycol 42:189216.[CrossRef][PubMed]
121. Xue J, Chen X, Selby D, Hung CY, Yu JJ, Cole GT. 2009. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77:31963208.[CrossRef][PubMed]
122. Mochon AB, Cutler JE. 2005. Is a vaccine needed against Candida albicans? Med Mycol 43:97115.[CrossRef][PubMed]
123. McGinnis MR. 1980. Laboratory Handbook of Medical Mycology. Academic Press, New York, NY.
124. Butka BJ, Bennett SR, Johnson AC. 1984. Disseminated inoculation blastomycosis in a renal transplant recipient. Am Rev Respir Dis 130:11801183.[PubMed]
125. Ramsey FK, Carter GR. 1952. Canine blastomycosis in the United States. J Am Vet Med Assoc 120:9398.[PubMed]
126. Larson DM, Eckman MR, Alber RL, Goldschmidt VG. 1983. Primary cutaneous (inoculation) blastomycosis: an occupational hazard to pathologists. Am J Clin Pathol 79:253255.[CrossRef][PubMed]
127. Sorensen RH, Cheu SH. 1964. Accidental cutaneous coccidioidal infection in an immune person. A case of an exogenous reinfection. Calif Med 100:4447.[PubMed]
128. Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives. 2008. Germs, Viruses, and Secrets: The Silent Proliferation of Bio-Laboratories in the United States. Serial No. 110-70. U.S. Government Printing Office, Washington, DC.
129. National Insitute of Allergy and Infectious Diseases, National Institutes of Health. Recombinant DNA Incident Reports 1977–May 2010. Freedom of Information Act case 377372010.
130. Wilder WH, McCollough CP. 1914. Sporotrichosis of the eye. J Am Med Assoc LXII:11561160.[CrossRef]

Tables

Generic image for table
Table 1.

Citation: Schell W. 2017. Mycotic Agents, p 147-162. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch7

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error